Theodore Schroeder
BOARD OF DIRECTORS
collegium pharma
Italy
Biography
Theodore Schroeder is the President, CEO, Director and co-founder of Zavante Therapeutics, Inc., a private biopharmaceutical company. Previously, Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc., and served as its President and Chief Executive Officer, and as a member of the board of directors, from May 2004 until its acquisition in May 2014 by Mallinckrodt Pharmaceuticals, Inc. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals, including senior vice president of North America sales and marketing and vice president and general manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb. Mr. Schroeder currently serves on the board of Cidara Therapeutics (Nasdaq:CDTX) and Otonomy, Inc., (Nasdaq: OTIC). Mr. Schroeder previously served on the boards of Hyperion Therapeutics, Incline Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder is a member of the Sharp Hospital Foundation board and chair of the BIOCOM board of directors. He holds a bachelor’s degree in management from Rutgers University.
Research Interest
Business and Management
